Commonwealth of Pennsylvania Public School Empls Retrmt SYS lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,847 shares of the life sciences company’s stock after selling 5 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Illumina were worth $1,882,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Advisory Services Network LLC bought a new stake in Illumina during the 1st quarter valued at approximately $117,000. Penserra Capital Management LLC boosted its stake in Illumina by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after purchasing an additional 102 shares during the period. Paradigm Asset Management Co. LLC boosted its stake in Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after purchasing an additional 50 shares during the period. Patten Group Inc. boosted its stake in Illumina by 2.7% during the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after purchasing an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. boosted its stake in Illumina by 11.3% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after purchasing an additional 100 shares during the period. Institutional investors own 93.32% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Commonwealth of Pennsylvania Public School Empls Retrmt SYS” was first published by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/illumina-inc-ilmn-stake-decreased-by-commonwealth-of-pennsylvania-public-school-empls-retrmt-sys/1600323.html.
Several analysts recently weighed in on ILMN shares. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a research note on Wednesday, May 31st. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Morgan Stanley restated an “underweight” rating and set a $122.00 target price (up previously from $115.00) on shares of Illumina in a research note on Monday, July 10th. Barclays PLC restated a “hold” rating and set a $150.00 target price on shares of Illumina in a research note on Wednesday, July 19th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $170.00 price objective on shares of Illumina in a research report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $182.15.
Shares of Illumina, Inc. (NASDAQ:ILMN) opened at 201.41 on Friday. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.34. The company’s 50-day moving average price is $199.76 and its 200-day moving average price is $181.17. The firm has a market capitalization of $29.41 billion, a PE ratio of 40.41 and a beta of 0.81.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662.00 million during the quarter, compared to the consensus estimate of $642.38 million. During the same period in the previous year, the business earned $0.86 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. Analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current year.
In other news, Director Jay T. Flatley sold 15,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the completion of the transaction, the director now directly owns 534,176 shares in the company, valued at $91,221,235.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Michel Bouchard sold 616 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,200.00. Following the transaction, the chief accounting officer now owns 15,161 shares of the company’s stock, valued at $3,032,200. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 175,188 shares of company stock valued at $33,870,937. Company insiders own 1.60% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with our FREE daily email newsletter.